Transient response to nivolumab and relapse after infliximab in a patient with primary cutaneous CD8‐positive aggressive epidermotropic cytotoxic T‐cell lymphoma
| Autor: | Stefan Schliep, Reinhard Dummer, Lucie Heinzerling, Gerhard Schuler, Frédéric Toussaint, Michael Erdmann, E. Grosch |
|---|---|
| Přispěvatelé: | University of Zurich, Toussaint, F, Heinzerling, L |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Skin Neoplasms 610 Medicine & health Dermatology CD8-Positive T-Lymphocytes 2708 Dermatology 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Internal medicine Female patient medicine Cytotoxic T cell Humans business.industry Treatment options 10177 Dermatology Clinic medicine.disease Infliximab Lymphoma Lymphoma T-Cell Cutaneous Disease-specific Survival Rate Nivolumab Neoplasm Recurrence Local business CD8 medicine.drug |
| Popis: | Primary cutaneous CD8+ aggressive epidermotropic T-cell lymphoma (CD8+ AECTCL) is a very rare subtype of cutaneous T-cell lymphoma. The frequency is less than 1% of all primary cutaneous lymphomas and prognosis is poor with a 5-year disease specific survival rate of 31% (1). Due to the rarity of this entity, there are no evidence-based treatment options. We report the case of a 70-year old female patient who presented with a red plaque with central ulceration on the left shin rapidly developing in two weeks. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|